EPiQ™ · The AI workspace
Build your nextradiopharmaceutical.
Automate the pipeline from target discovery to a de-risked lead: 30+ models, reproducible workflows, no infrastructure to manage.
30+ models
Published engines and Epitorix's own
The modules
Every step, one workspace.
EPiQ is Epitorix's modular AI workspace for radiopharmaceutical design. Over 30 models, published and in-house, cover target discovery, binding-site analysis, molecular generation, affinity ranking, optimization, off-target prediction, cell-type risk, organ risk and biodistribution modeling. Run any module alone, or connect them into one end-to-end workflow.
- Reproducible workflows
- No-code connections
- Transparent process
- No infrastructure to manage
We design.We optimize.We de-risk your lead.
End to end
From first design to a development candidate.
We design your pipeline from candidate generation through affinity, stability, toxicity and biodistribution to a lead optimized for preclinical development, minimizing the risk of failure at every stage.
Generation · Affinity · Stability · Toxicity · Biodistribution · Live platform · Dashboard
- Target — Design (EPiQ · Xenoclea).
- Binding-site analysis — Design (EPiQ · Xenoclea).
- Generation — Design (EPiQ · Xenoclea). ~10,000: about 10,000 site- and target-specific candidates.
- Affinity ranking — Design (EPiQ · Xenoclea). ~1,000/s: about 1,000 molecules per second, ranked by predicted Kd; Pearson R 0.84 for peptides in internal benchmarks.
- Optimization — Design (EPiQ · Xenoclea).
- Off-target — De-risk (PharmPhax · PharmacoLaw). ~1 hour: the whole proteome in about one hour, over 90% recall on known off-target interactions.
- Biodistribution & organ risk — De-risk (PharmPhax · PharmacoLaw). up to 93%: organ, cell-type and biodistribution risk; up to 93% accuracy detecting reported development and safety liabilities in retrospective analyses of radiopharmaceuticals with documented clinical outcomes.
- In vitro — Advance (Therapeutic Pipeline). 10+ labs: Epi-labs — over 10 labs across the United States.
- In vivo validation — Advance (Therapeutic Pipeline).
- Translational & regulatory — Advance (Therapeutic Pipeline).
- Clinic — Advance (Therapeutic Pipeline).
How EPiQ works
We design your pipeline end to end
From generating possible lead pharmaceuticals all the way to development candidates, optimized to minimize the risk of failure at every stage.
- AffinityAffinity ranking
- StabilitySerum stability
- ToxicityOff-target prediction, cell-type risk assessment
- BiodistributionBiodistribution modeling
Powered by literature and Epitorix
Generator engines, published and our own.
Published and in-house generators, side by side — selected per target, not defaulted to one.
- Boltz
Prot1 - R
Fpeptides - Pep
Flow - HYDRA
- Diff
Pep Builder - Colab
Design - Boltz
Gen - Boltz
Design1 - CyclicMPNN
- PepHAR
- EpitorixRL
- Evo
Diff - Pep
Tune - Epitorix
Design Peptide - Epitorix
Design PeptideSC
Epitorix in-house engine
Our in-house models
We are not just combining published models. We have our own.
Architectures designed by Epitorix, trained on data we generated ourselves and validated at the bench — for peptides, antibodies, nanobodies and mini-proteins.
100%
of designs taken to the bench bound their target
In internal benchmarks; the number of designs, targets and the assay threshold are not yet published.
0.84
Pearson R, predicted vs measured pKd
Peptides, in internal benchmarks; a preprint describing the evaluation is forthcoming.
Epitorix is a research and development platform. Its predictions are not intended for patient-level or clinical decision-making.
Epi-labs
Design in software. Confirm at the bench.
Experimental validation from 10+ labs across the United States, reachable from the workspace with one drag-and-drop — design and experiment in one loop.
Epitorix AI
A specialized RAG system at your fingertips.
Every model, dataset and paper in EPiQ, queryable in one place, with frontier reasoning on top.
Academic access
Eligible academics get unlimited access to Epitorix's top-tier models.
Ask about academic accessAssessment
“EPiQ™ compresses months of complex, PhD-level research into mere hours.”
“By leveraging world-class, peer-reviewed generative AI models to design lead pharmaceuticals, workflows that once took my postdocs months for a single target are now fully automated and completed in just a couple of hours. Absolutely amazing.”
FAQ
Clear answers to common questions.
EPiQ™ is Epitorix's modular AI workspace for target discovery, binding-site analysis, molecular generation, affinity ranking, optimization, off-target prediction, cell-type risk assessment, organ-risk prediction, and biodistribution modeling. Users can apply individual modules or connect them into an end-to-end workflow.
As between Epitorix and the user, the user retains rights to the molecular outputs generated through their authorized EPiQ™ account, subject to the applicable platform agreement. Epitorix does not claim ownership of a user's generated outputs solely because they were created using the platform.
No. EPiQ™ is an AI-based generative platform, and AI models may independently generate identical or substantially similar molecules for different users, particularly when users provide similar targets, binding sites, constraints, or design objectives. Epitorix does not guarantee that every generated structure will be exclusive, novel, or patentable.
No. Epitorix is a research and development platform. Its predictions are not intended to independently diagnose, treat, prevent, or manage disease, and they should not be used as the sole basis for patient-level or clinical decisions.
Meet Xenoclea
Describe, rather than configure.
Xenoclea is the conversational AI orchestrator built into EPiQ. Describe your target in plain language; it plans the work across Epitorix's models and returns ranked, structure-backed designs.
- Epitorix AI: Welcome to Epitorix! 👋 How can I assist with your radiopharmaceutical design today?02:47 PM
Contact
Bring us a target.
A target to design against, a candidate to de-risk, or the pipeline data.
Laboratory bench · liquid handler and assay plates